Cargando…

Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial

BACKGROUND: One‐third of peripheral intravenous catheters (PIVCs) fail from inflammatory or infectious complications, causing substantial treatment interruption and replacement procedures. OBJECTIVES: We aimed to compare complications between integrated PIVCs (inbuilt extension sets, wings, and flat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rickard, Claire M., Larsen, Emily, Walker, Rachel M., Mihala, Gabor, Byrnes, Joshua, Saiyed, Masnoon, Cooke, Marie, Finucane, Julie, Carr, Peter J., Marsh, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099685/
https://www.ncbi.nlm.nih.gov/pubmed/36372995
http://dx.doi.org/10.1002/jhm.12995
_version_ 1785025107319586816
author Rickard, Claire M.
Larsen, Emily
Walker, Rachel M.
Mihala, Gabor
Byrnes, Joshua
Saiyed, Masnoon
Cooke, Marie
Finucane, Julie
Carr, Peter J.
Marsh, Nicole
author_facet Rickard, Claire M.
Larsen, Emily
Walker, Rachel M.
Mihala, Gabor
Byrnes, Joshua
Saiyed, Masnoon
Cooke, Marie
Finucane, Julie
Carr, Peter J.
Marsh, Nicole
author_sort Rickard, Claire M.
collection PubMed
description BACKGROUND: One‐third of peripheral intravenous catheters (PIVCs) fail from inflammatory or infectious complications, causing substantial treatment interruption and replacement procedures. OBJECTIVES: We aimed to compare complications between integrated PIVCs (inbuilt extension sets, wings, and flattened bases) and traditional nonintegrated PIVCs. DESIGNS, SETTINGS AND PARTICIPANTS: A centrally randomized, controlled, superiority trial (with allocation concealment until study entry) was conducted in three Australian hospitals. Medical–surgical patients (one PIVC each) requiring intravenous therapy for >24 h were studied. MAIN OUTCOME MEASURES: The primary outcome was device failure (composite: occlusion, infiltration, phlebitis, dislodgement, local, or bloodstream infection). Infection endpoints were assessor‐masked. The secondary outcomes were: failure type, first‐time insertion success, tip colonization, insertion pain, dwell time, mortality, costs, health‐related quality of life, clinician, and patient satisfaction. RESULTS: Out of 1759 patients randomized (integrated PIVC, n = 881; nonintegrated PIVC, n = 878), 1710 (97%) received a PIVC and were in the modified intention‐to‐treat analysis (2269 PIVC‐days integrated; 2073 PIVC‐days nonintegrated). Device failure incidence was 35% (145 per 1000 device‐days) nonintegrated, and 33% (124 per 1000 device‐days) integrated PIVCs. INTERVENTION: Integrated PIVCs had a significantly lower failure risk (adjusted [sex, infection, setting, site, gauge] hazard ratio [HR]: 0.82 [95% confidence interval, CI: 0.69–0.96], p = .015). The per‐protocol analysis was consistent (adjusted HR: 0.80 [95% CI: 0.68–0.95], p = .010). Integrated PIVCs had significantly longer dwell (top quartile ≥ 95 vs. ≥84 h). Mean per‐patient costs were not statistically different. CONCLUSIONS: PIVC failure is common and complex. Significant risk factors include sex, infection at baseline, care setting, insertion site, catheter gauge, and catheter type. Integrated PIVCs can significantly reduce the burden of PIVC failure on patients and the health system.
format Online
Article
Text
id pubmed-10099685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100996852023-04-14 Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial Rickard, Claire M. Larsen, Emily Walker, Rachel M. Mihala, Gabor Byrnes, Joshua Saiyed, Masnoon Cooke, Marie Finucane, Julie Carr, Peter J. Marsh, Nicole J Hosp Med Original Research BACKGROUND: One‐third of peripheral intravenous catheters (PIVCs) fail from inflammatory or infectious complications, causing substantial treatment interruption and replacement procedures. OBJECTIVES: We aimed to compare complications between integrated PIVCs (inbuilt extension sets, wings, and flattened bases) and traditional nonintegrated PIVCs. DESIGNS, SETTINGS AND PARTICIPANTS: A centrally randomized, controlled, superiority trial (with allocation concealment until study entry) was conducted in three Australian hospitals. Medical–surgical patients (one PIVC each) requiring intravenous therapy for >24 h were studied. MAIN OUTCOME MEASURES: The primary outcome was device failure (composite: occlusion, infiltration, phlebitis, dislodgement, local, or bloodstream infection). Infection endpoints were assessor‐masked. The secondary outcomes were: failure type, first‐time insertion success, tip colonization, insertion pain, dwell time, mortality, costs, health‐related quality of life, clinician, and patient satisfaction. RESULTS: Out of 1759 patients randomized (integrated PIVC, n = 881; nonintegrated PIVC, n = 878), 1710 (97%) received a PIVC and were in the modified intention‐to‐treat analysis (2269 PIVC‐days integrated; 2073 PIVC‐days nonintegrated). Device failure incidence was 35% (145 per 1000 device‐days) nonintegrated, and 33% (124 per 1000 device‐days) integrated PIVCs. INTERVENTION: Integrated PIVCs had a significantly lower failure risk (adjusted [sex, infection, setting, site, gauge] hazard ratio [HR]: 0.82 [95% confidence interval, CI: 0.69–0.96], p = .015). The per‐protocol analysis was consistent (adjusted HR: 0.80 [95% CI: 0.68–0.95], p = .010). Integrated PIVCs had significantly longer dwell (top quartile ≥ 95 vs. ≥84 h). Mean per‐patient costs were not statistically different. CONCLUSIONS: PIVC failure is common and complex. Significant risk factors include sex, infection at baseline, care setting, insertion site, catheter gauge, and catheter type. Integrated PIVCs can significantly reduce the burden of PIVC failure on patients and the health system. John Wiley and Sons Inc. 2022-11-13 2023-01 /pmc/articles/PMC10099685/ /pubmed/36372995 http://dx.doi.org/10.1002/jhm.12995 Text en © 2022 The Authors. Journal of Hospital Medicine published by Wiley Periodicals LLC on behalf of Society of Hospital Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Rickard, Claire M.
Larsen, Emily
Walker, Rachel M.
Mihala, Gabor
Byrnes, Joshua
Saiyed, Masnoon
Cooke, Marie
Finucane, Julie
Carr, Peter J.
Marsh, Nicole
Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title_full Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title_fullStr Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title_full_unstemmed Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title_short Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): A randomized controlled trial
title_sort integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (optimum): a randomized controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099685/
https://www.ncbi.nlm.nih.gov/pubmed/36372995
http://dx.doi.org/10.1002/jhm.12995
work_keys_str_mv AT rickardclairem integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT larsenemily integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT walkerrachelm integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT mihalagabor integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT byrnesjoshua integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT saiyedmasnoon integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT cookemarie integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT finucanejulie integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT carrpeterj integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial
AT marshnicole integratedversusnonintegratedperipheralintravenouscatheterinhospitalizedadultsoptimumarandomizedcontrolledtrial